Biohaven Pharmaceutical Holding (BHVN) Unlikely to See Success in Alzheimer Study - Morgan Stanley

December 24, 2020 8:20 AM EST
Get Alerts BHVN Hot Sheet
Price: $95.00 -5.38%

Rating Summary:
    11 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 8 | New: 61
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Morgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $73.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) ahead of top line data expected from the T2 Protect AD study which is expected in the next few weeks.

The analyst stated "Our expectation is low due to low probability of success for AD drugs and high bar for statistical outcomes. But if successful, trial design suggests clinically meaningful improvements and we see 45-65% upside".

For an analyst ratings summary and ratings history on Biohaven Pharmaceutical Holding click here. For more ratings news on Biohaven Pharmaceutical Holding click here.

Shares of Biohaven Pharmaceutical Holding closed at $91.23 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Morgan Stanley